of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria—What has changed and why?

L Bertero, F Massa, J Metovic, R Zanetti, I Castellano… - Virchows Archiv, 2018 - Springer
The TNM classification of malignant tumours is a mainstay tool in clinical practice and
research for prognostic assessment of patients, treatment allocation and trial enrolment, as …

White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part II, update …

NM Kulkarni, L Mannelli, M Zins, PR Bhosale… - Abdominal …, 2020 - Springer
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive gastrointestinal malignancy
with a poor 5-year survival rate. Its high mortality rate is attributed to its aggressive biology …

of the AJCC cancer staging manual: pancreas and hepatobiliary cancers

YS Chun, TM Pawlik, JN Vauthey - Annals of surgical oncology, 2018 - Springer
The American Joint Committee on Cancer (AJCC) Staging Manual represents the standard
for classifying patients with pancreas and hepatobiliary cancers, predicting prognosis, and …

Multi-institutional validation study of the American Joint Commission on Cancer changes for T and N staging in patients with pancreatic adenocarcinoma

PJ Allen, D Kuk, C Fernandez-del Castillo… - Annals of …, 2017 - journals.lww.com
Objective: The aim of this study was to evaluate and validate the proposed 8th edition
American Joint Committee on Cancer (AJCC) system for T and N staging of pancreatic …

International validation of the eighth edition of the American Joint Committee on Cancer (AJCC) TNM staging system in patients with resected pancreatic cancer

S Van Roessel, GG Kasumova, J Verheij… - JAMA …, 2018 - jamanetwork.com
Importance The recently released eighth edition of the American Joint Committee on Cancer
TNM staging system for pancreatic cancer seeks to improve prognostic accuracy but lacks …

Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer

CA McIntyre, A Grimont, J Park, Y Meng, WJ Sisso… - Cancer Cell, 2024 - cell.com
KRAS mutations in pancreatic ductal adenocarcinoma (PDAC) are suggested to vary in
oncogenicity but the implications for human patients have not been explored in depth. We …

Validation of the American Joint Commission on Cancer (AJCC) staging system for patients with pancreatic adenocarcinoma: a Surveillance, Epidemiology and End …

SK Kamarajah, WR Burns, TL Frankel, CS Cho… - Annals of surgical …, 2017 - Springer
Background The 8th edition of the AJCC staging system for pancreatic cancer incorporated
several significant changes. This study sought to evaluate this staging system and assess its …

CT abnormalities of the pancreas associated with the subsequent diagnosis of clinical stage I pancreatic ductal adenocarcinoma more than 1 year later: a case-control …

F Toshima, R Watanabe, D Inoue… - American Journal of …, 2021 - Am Roentgen Ray Soc
Please see the Editorial Comment by Neeraj Lalwani discussing this article. To listen to the
podcast associated with this article, please select one of the following: iTunes, Google Play …

Proposed modification of the 8th edition of the AJCC staging system for pancreatic ductal adenocarcinoma

S Shi, J Hua, C Liang, Q Meng, D Liang, J Xu… - Annals of …, 2019 - journals.lww.com
Objective: The aim of this study was to improve the 8th edition (8th) of the American Joint
Committee on Cancer (AJCC) staging system for pancreatic ductal adenocarcinoma …

IPMN-associated pancreatic cancer: Survival, prognostic staging and impact of adjuvant chemotherapy

J Kaiser, C Scheifele, U Hinz, CS Leonhardt… - European Journal of …, 2022 - Elsevier
Background Intraductal papillary mucinous neoplasm (IPMN)-associated carcinoma is a
subtype of pancreatic cancer for which prognostic factors, the validity of the AJCC/UICC …